Niagen Bioscience Q2 sales beat estimates
Overview
Niagen Bioscience Q2 net sales rise 37% to $31.1 mln, beating estimates, per LSEG data
Net income reaches $3.6 mln, up from breakeven in prior year period
Company raises full-year 2025 revenue growth outlook to 22%-27%
Outlook
Niagen Bioscience raises 2025 revenue growth outlook to 22%-27%
Company expects slight improvement in gross margin year-over-year
Sales and marketing expenses to rise, but decrease as percentage of sales
General and administrative expenses to increase by $7.0 to $8.0 mln
Result Drivers
TRU NIAGEN SALES - Sales reached $22.7 mln, growing 22%, driven by strong e-commerce performance
NIAGEN INGREDIENT SALES - Increased 135% to $7.4 mln, including food-grade and pharmaceutical-grade sales
GROSS MARGIN IMPROVEMENT - Increased 480 basis points to 65.0% due to changes in product and business mix
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $31.12 mln | $28.30 mln (5 Analysts) |
Q2 Net Income | $3.61 mln | ||
Q2 Gross Profit | $20.23 mln | ||
Q2 Operating Expenses | $17.04 mln | ||
Q2 Operating Income | $3.18 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Niagen Bioscience Inc is $16.00, about 42.8% above its August 5 closing price of $9.16
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 55 three months ago
Press Release:
